Why The Narrative Around Sangamo Therapeutics Is Shifting After Recent Analyst and FDA Updates [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
The fair value estimate has dipped from $4.10 to $3.25, with analysts adjusting assumptions based on both encouraging milestones and persistent headwinds. These include a higher discount rate and notably improved revenue projections. For investors navigating these shifts, staying informed on evolving analyst sentiment will be key to understanding future developments in Sangamo's narrative. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Sangamo Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Analysts have recognized Sangamo Therapeutics' ability to extend its cash runway into the first quarter of 2026. This is seen as a positive signal for operational stability in the near term. The FDA's reaffirmation of an accelerated approval path using eGFR slope as an endpoint in Fabry disease programs has been viewed as an encouraging regulatory milestone. ?? Bearish Takeaways Barclays recently
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewswire
- How Recent Developments Are Rewriting the Story for Sangamo Therapeutics [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseGlobeNewswire
- Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
SGMO
Earnings
- 11/6/25 - Miss
SGMO
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- SGMO's page on the SEC website